Early Detection of Bladder Cancer Possible With New Screening Tool
Canine TCC/UC/bladder cancer -- Breen Lab @ NCSU
- Canine Transitional Cell Carcinoma (TCC) /Urothelial Carcinoma (UC)/bladder cancer in dogs – New research provides an opportunity for early detection.
Matthew Breen PhD CBiol FRSB
Oscar J. Fletcher Distinguished Professor of
Comparative Oncology Genetics
Shelly Vaden, DVM, PhD, DACVIM
Professor of Internal Medicine
President of the American Society of Veterinary Nephrology and Urology
North Carolina State University,
College of Veterinary Medicine,
Raleigh, NC 27607
Canine transitional cell carcinoma (TCC), also known as urothelial carcinoma (UC), is the most common cancer of the canine urinary tract (1). Across all breeds the cancer represents an estimated 1-2% of all canine cancer, and with over 4-6 million cancers diagnosed in pet dogs each year in the US, the number of canine TCCs/UCs is estimated to exceed 50,000. However a group of 13 breeds, including the Beagle, has a much higher chance of developing the cancer. The cancer is generally a disease of mid to late life, with over 95% of cases occurring in dogs age 6 years and older. TCC/UC affects the bladder, urethra, and kidneys of male and female dogs and also the prostate of males. Clinical presentation of advancing TCC/UC is shared with other much more common urinary tract disorders, including cystitis and prostatitis. These may include one or more of the following: straining to urinate; repeated frequent attempts to urinate; blood in the urine; and bacterial infection.
Go to Sentinel Biomedical to GET More Information on THE TEST...
BRAF Mutations in Canine Cancers
Hiroyuki Mochizuki, Katherine Kennedy, Susan G. Shapiro, Matthew Breen
Detection of BRAF Mutation in Urine DNA as a Molecular Diagnostic for Canine Urothelial and Prostatic Carcinoma
Hiroyuki Mochizuki, Susan G. Shapiro, Matthew Breen
Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer—Evidence for a Relevant Model System and Urine-Based Diagnostic Test
Brennan Decker, Heidi G. Parker, Deepika Dhawan, Erika M. Kwon, Eric Karlins, Brian W. Davis, José A. Ramos-Vara, Patty L. Bonney, Elizabeth A. McNiel, Deborah W. Knapp and Elaine A. Ostrander
Learn about Sentinel Biomedical's newest product: CADET BRAF Mutation Detection Assay, designed for the early detection and monitoring of canine bladder cancer or canine transitional cell carcinoma (TCC)/urothelial carcinoma (UC). Review the research, findings and how the test works. (33:15) with lead researcher Dr. Matthew Breen, PhD CBiol FRSB